Sonnappa S, et al. - This meta-analysis of observational real-life asthma studies assessed the treatment impact of extrafine inhaled corticosteroids (ICSs) (mass median aerodynamic diameter, <2 μm) by comparing their efficacy with that of fine-particle ICSs, administered as ICS monotherapy or ICS-long-acting β-agonist combination therapy. Findings revealed that extrafine ICSs versus fine-particle ICSs had significantly higher odds of achieving asthma control with lower exacerbation rates at significantly lower prescribed doses.